Loading
MM
Miromatrix Medical Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Barry John Joseph, was filed 30 Mar 2023.
Miromatrix Medical Inc.: what insiders have been doing
Miromatrix Medical Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Miromatrix Medical Inc. has had no insider filing for more than a year; the last one goes back to 13 December 2023.
Looking back to 2021, when coverage begins, insiders filed 8 purchases and no sales.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
67
Thresholds
n/a
Buy Volume
€340,114
8 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$820.9k
Gross profitUS$390.4k48% margin
Net income-US$25.8M-3142.2% margin
Last declaration on 13 December 2023
Declarations67 total
58,368 sharesCommon StockSEC:0001415889-23-016385:1
87,500 sharesCommon StockSEC:0001415889-23-016371:1
67,413 sharesCommon StockSEC:0001415889-23-016375:1
67,413 sharesCommon StockSEC:0001415889-23-016386:1
54,201 sharesCommon StockSEC:0001415889-23-016380:1
20,000 sharesCommon StockSEC:0001415889-23-016373:1
52,593 sharesCommon StockSEC:0001415889-23-016377:0
308,775 sharesCommon StockSEC:0001415889-23-016371:0
66,943 sharesCommon StockSEC:0001415889-23-016386:0
62,092 sharesCommon StockSEC:0001415889-23-016385:0
56,260 sharesCommon StockSEC:0001415889-23-016380:0
66,943 sharesCommon StockSEC:0001415889-23-016375:0
31,250 sharesCommon StockSEC:0001415889-23-016373:0
54,201 sharesCommon StockSEC:0001415889-23-016377:1
54,201 shares0Common StockSEC:0001415889-23-009213:0
54,201 shares0Common StockSEC:0001415889-23-009228:0
54,201 shares0Common StockSEC:0001415889-23-009222:0
54,201 shares0Common StockSEC:0001415889-23-009216:0
54,201 shares0Common StockSEC:0001415889-23-009212:0
6,250 shares@ US$1.6073.5% of flowCommon StockSEC:0001415889-23-005635:0
Canonical exit: 8 Jun 2023 (T+90)
31,250 shares@ US$1.60100.0% of flowCommon StockSEC:0001415889-23-005637:0
Canonical exit: 8 Jun 2023 (T+90)
31,250 shares@ US$1.60100.0% of flowCommon StockSEC:0001415889-23-005631:0
Canonical exit: 8 Jun 2023 (T+90)
31,250 shares@ US$1.60100.0% of flowCommon StockSEC:0001415889-23-005630:0
Canonical exit: 8 Jun 2023 (T+90)
31,250 shares@ US$1.60100.0% of flowCommon StockSEC:0001415889-23-005633:0
Canonical exit: 8 Jun 2023 (T+90)
31,250 shares@ US$1.60100.0% of flowCommon StockSEC:0001415889-23-005634:0
Canonical exit: 8 Jun 2023 (T+90)
25 of 67 declarations
About Miromatrix Medical Inc.
Miromatrix Medical Inc. is a U.S.-based biotechnology company that was previously listed on the NASDAQ Capital Market in the United States (United States) under the ticker MIRO and operated in a highly specialized corner of regenerative medicine and organ engineering. The company was founded in 2009 out of research originating at the University of Minnesota, and its core scientific platform is built around proprietary perfusion decellularization and recellularization technology. In practical terms, Miromatrix’s approach involves removing cells from a donor animal organ to preserve the underlying extracellular matrix and vascular architecture, then repopulating that scaffold with human cells in an effort to create a transplantable bioengineered organ.
Miromatrix’s development pipeline has focused on three headline programs: mirokidney®, a fully implantable engineered kidney; miroliver®, a fully implantable engineered liver; and miroliverELAP®, an external bioengineered liver-assist system for patients with acute liver failure. The company has also described longer-term ambitions to extend its platform to other organs, including lungs, pancreas, and heart tissue. In investor terms, this is a classic high-risk, high-science platform story: the commercial opportunity is large, but the path to product approval, clinical adoption, and scalable manufacturing is complex and highly regulated. Miromatrix has also highlighted that its work is supported by a sizable patent portfolio and by prior clinical and preclinical data generated from decellularized matrix products.
Read moreShow less
From a competitive standpoint, Miromatrix has occupied a niche position rather than competing in a broad therapeutic market. Its differentiation comes from the combination of organ architecture preservation, human-cell reseeding, and the long-term goal of providing a new source of transplantable organs. That said, the company’s public-market profile changed materially after the 2023 acquisition by United Therapeutics. In December 2023, Miromatrix became a wholly owned subsidiary of United Therapeutics, and the former MIRO shares ceased trading following the transaction. For investors, that is a critical point: Miromatrix should now be understood primarily as an acquired technology platform rather than a standalone listed equity.
Geographically, the company is headquartered in Eden Prairie, Minnesota, giving it strong ties to the U.S. biomedical research ecosystem. Its historical footprint has been concentrated in the United States, where its technologies, intellectual property, and clinical development efforts are centered. Recent corporate headlines have been dominated by the acquisition itself and the related contingent value right structure tied to the first implantation of mirokidney in a human patient under specified clinical conditions. Overall, Miromatrix remains an important case study in advanced biotech, combining a long-dated medical mission with meaningful strategic value inside a larger U.S. life sciences platform.
